dalteparin has been researched along with End Stage Liver Disease in 2 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
End Stage Liver Disease: Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kishore, SB | 1 |
| Lewindon, P | 1 |
| Noble, C | 1 |
| Balouch, F | 1 |
| Camden, R | 1 |
| Ludwig, S | 1 |
2 other studies available for dalteparin and End Stage Liver Disease
| Article | Year |
|---|---|
Enoxaparin is safe and effective for restoring and preserving forward portal venous flow in children with end-stage liver disease.
Topics: Anticoagulants; Child; End Stage Liver Disease; Enoxaparin; Humans; Portal Vein | 2023 |
Prophylaxis against venous thromboembolism in hospitalized medically ill patients: Update and practical approach.
Topics: Adult; Aged; End Stage Liver Disease; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Hospitaliza | 2014 |